Cargando…
Heparin for patients with coronavirus disease 2019 and hypercoagulation complications: A cohort study
BACKGROUND: Thrombotic complications of coronavirus disease 2019 (COVID-19) are a worrisome aspect of the disease due to their high incidence in critically ill patients and their poor clinical outcomes. The aim of this study was to compare the effectiveness of unfractionated heparin (UFH) and low mo...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238275/ https://www.ncbi.nlm.nih.gov/pubmed/35784948 http://dx.doi.org/10.1016/j.amsu.2022.104042 |
_version_ | 1784737008851091456 |
---|---|
author | Fachri, Muhammad Hatta, Mochammad Tarigan, Sefia Nabila Nur Azmi Akaputra, Risky Dwiyanti, Ressy Syukri, Ahmad Junita, Ade Rifka Primaguna, Muhammad Reza Febrianty, Andini |
author_facet | Fachri, Muhammad Hatta, Mochammad Tarigan, Sefia Nabila Nur Azmi Akaputra, Risky Dwiyanti, Ressy Syukri, Ahmad Junita, Ade Rifka Primaguna, Muhammad Reza Febrianty, Andini |
author_sort | Fachri, Muhammad |
collection | PubMed |
description | BACKGROUND: Thrombotic complications of coronavirus disease 2019 (COVID-19) are a worrisome aspect of the disease due to their high incidence in critically ill patients and their poor clinical outcomes. The aim of this study was to compare the effectiveness of unfractionated heparin (UFH) and low molecular weight heparin (LMWH) (fondaparinux) in hospitalized COVID-19 patients with hypercoagulable complications. MATERIAL AND METHODS: The study design used a retrospective cohort approach incorporating pre- and post-tests via secondary data extracted from the medical records of inpatients with confirmed COVID-19. RESULTS: Among the 98 individuals studied (52% women; 30.6% at >60 years of age), 35 patients received UFH, while the remaining 63 patients received LMWH (fondaparinux). The greatest decrease in the D-dimer value (0.01 ± 0.5 g fibrinogen equivalent units/mL) was observed in 12 (34.3%) and 15 (23.8%) patients in the UFH and LMWH (fondaparinux) groups, respectively. Most inpatients with confirmed COVID-19 were aged 50–59 years and were women. CONCLUSION: There was a tendency toward increased D-dimer, normal prothrombin time, normal activated partial thromboplastin clotting time, and increased fibrinogen values in each COVID-19 patient. The results demonstrated a significant relationship between the D-dimer and prothrombin time parameter in confirmed COVID-19 inpatients. |
format | Online Article Text |
id | pubmed-9238275 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-92382752022-06-28 Heparin for patients with coronavirus disease 2019 and hypercoagulation complications: A cohort study Fachri, Muhammad Hatta, Mochammad Tarigan, Sefia Nabila Nur Azmi Akaputra, Risky Dwiyanti, Ressy Syukri, Ahmad Junita, Ade Rifka Primaguna, Muhammad Reza Febrianty, Andini Ann Med Surg (Lond) Cohort Study BACKGROUND: Thrombotic complications of coronavirus disease 2019 (COVID-19) are a worrisome aspect of the disease due to their high incidence in critically ill patients and their poor clinical outcomes. The aim of this study was to compare the effectiveness of unfractionated heparin (UFH) and low molecular weight heparin (LMWH) (fondaparinux) in hospitalized COVID-19 patients with hypercoagulable complications. MATERIAL AND METHODS: The study design used a retrospective cohort approach incorporating pre- and post-tests via secondary data extracted from the medical records of inpatients with confirmed COVID-19. RESULTS: Among the 98 individuals studied (52% women; 30.6% at >60 years of age), 35 patients received UFH, while the remaining 63 patients received LMWH (fondaparinux). The greatest decrease in the D-dimer value (0.01 ± 0.5 g fibrinogen equivalent units/mL) was observed in 12 (34.3%) and 15 (23.8%) patients in the UFH and LMWH (fondaparinux) groups, respectively. Most inpatients with confirmed COVID-19 were aged 50–59 years and were women. CONCLUSION: There was a tendency toward increased D-dimer, normal prothrombin time, normal activated partial thromboplastin clotting time, and increased fibrinogen values in each COVID-19 patient. The results demonstrated a significant relationship between the D-dimer and prothrombin time parameter in confirmed COVID-19 inpatients. Elsevier 2022-06-28 /pmc/articles/PMC9238275/ /pubmed/35784948 http://dx.doi.org/10.1016/j.amsu.2022.104042 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Cohort Study Fachri, Muhammad Hatta, Mochammad Tarigan, Sefia Nabila Nur Azmi Akaputra, Risky Dwiyanti, Ressy Syukri, Ahmad Junita, Ade Rifka Primaguna, Muhammad Reza Febrianty, Andini Heparin for patients with coronavirus disease 2019 and hypercoagulation complications: A cohort study |
title | Heparin for patients with coronavirus disease 2019 and hypercoagulation complications: A cohort study |
title_full | Heparin for patients with coronavirus disease 2019 and hypercoagulation complications: A cohort study |
title_fullStr | Heparin for patients with coronavirus disease 2019 and hypercoagulation complications: A cohort study |
title_full_unstemmed | Heparin for patients with coronavirus disease 2019 and hypercoagulation complications: A cohort study |
title_short | Heparin for patients with coronavirus disease 2019 and hypercoagulation complications: A cohort study |
title_sort | heparin for patients with coronavirus disease 2019 and hypercoagulation complications: a cohort study |
topic | Cohort Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238275/ https://www.ncbi.nlm.nih.gov/pubmed/35784948 http://dx.doi.org/10.1016/j.amsu.2022.104042 |
work_keys_str_mv | AT fachrimuhammad heparinforpatientswithcoronavirusdisease2019andhypercoagulationcomplicationsacohortstudy AT hattamochammad heparinforpatientswithcoronavirusdisease2019andhypercoagulationcomplicationsacohortstudy AT tarigansefianabilanurazmi heparinforpatientswithcoronavirusdisease2019andhypercoagulationcomplicationsacohortstudy AT akaputrarisky heparinforpatientswithcoronavirusdisease2019andhypercoagulationcomplicationsacohortstudy AT dwiyantiressy heparinforpatientswithcoronavirusdisease2019andhypercoagulationcomplicationsacohortstudy AT syukriahmad heparinforpatientswithcoronavirusdisease2019andhypercoagulationcomplicationsacohortstudy AT junitaaderifka heparinforpatientswithcoronavirusdisease2019andhypercoagulationcomplicationsacohortstudy AT primagunamuhammadreza heparinforpatientswithcoronavirusdisease2019andhypercoagulationcomplicationsacohortstudy AT febriantyandini heparinforpatientswithcoronavirusdisease2019andhypercoagulationcomplicationsacohortstudy |